HEMOGENYX PHARMACEUTICALS PLC

Pre-Annual General Meeting Information • Nov 14, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3900W

Hemogenyx Pharmaceuticals PLC

14 November 2017

Hemogenyx Pharmaceuticals Plc

("Hemogenyx" or the "Company")

Notice of AGM

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, confirms that the Notice of the Annual General Meeting ("AGM") was sent to shareholders yesterday. 

This document is available to view on the company website: www.hemogenyx.com 

The AGM is to be held at 10:00am on Thursday 7 December 2017 at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London EC4M 7RD.  

Enquiries:

Hemogenyx Pharmaceuticals Limited		www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder		Via Walbrook PR
Dr Robin Campbell, Chairman
Optiva Securities Ltd		Tel: +44 (0)20 3137 1902
Christian Dennis
Shard Capital Partners LLP		Tel: +44 (0)20 7186 9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited		Tel: +44 (0)20 7469 0930
Lucy Williams/Duncan Vasey
Walbrook PR	Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com
Paul McManus	Mob: +44 (0)7980 541 893

About Hemogenyx Pharmaceuticals Plc

Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, Hemogenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. Hemogenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company's leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. Hemogenyx's two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NOAFFDSILFWSEIF